ConductScience.org, home

Paper42011199

Spatiotemporally reprogrammed L-arginine metabolic nanoregulator potentiates immunotherapy.

Cheng Q and 6 others. Bioact Mater, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Spatiotemporally reprogrammed L-arginine metabolic nanoregulator potentiates immunotherapy. Papers, record 42011199. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42011199

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Spatiotemporally reprogrammed L-arginine metabolic nanoregulator potentiates immunotherapy.
PubMed
Journal
Bioact Mater
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cheng QQian
2Shi XXiaolei
3Qin QQushuhua
4Chen YYuzhe
5Wang JJiawei
6Wang LLin
7Wang ZZheng

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References53

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136229606Metabolic communication in the tumour-immune microenvironment.Nat Cell Biol2022https://conductscience.org/library/papers/36229606PubMed
237436776Engineered Living Materials for Advanced Diseases Therapy.Adv Mater2025https://conductscience.org/library/papers/37436776PubMed
337536496L-Arginine self-delivery supramolecular nanodrug for NO gas therapy.Acta Biomater2023https://conductscience.org/library/papers/37536496PubMed
435120665Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.Cell2022https://conductscience.org/library/papers/35120665PubMed
526359979Nutrient Competition: A New Axis of Tumor Immunosuppression.Cell2015https://conductscience.org/library/papers/26359979PubMed
637046001Dynamics and specificities of T cells in cancer immunotherapy.Nat Rev Cancer2023https://conductscience.org/library/papers/37046001PubMed
733837297Systemic immunity in cancer.Nat Rev Cancer2021https://conductscience.org/library/papers/33837297PubMed
839739630Nano-Armed Limosilactobacillus reuteri for Enhanced Photo-Immunotherapy and Microbiota Tryptophan Metabolism against Colorectal Cancer.Adv Sci (Weinh)2025https://conductscience.org/library/papers/39739630PubMed
933177494Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy.Cell Death Dis2020https://conductscience.org/library/papers/33177494PubMed
1028159861Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy.Cancer Res2017https://conductscience.org/library/papers/28159861PubMed
1126321679Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.Cell2015https://conductscience.org/library/papers/26321679PubMed
1227745970L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity.Cell2016https://conductscience.org/library/papers/27745970PubMed
1339558532Opportunities and Challenges of Arginase Inhibitors in Cancer: A Medicinal Chemistry Perspective.J Med Chem2024https://conductscience.org/library/papers/39558532PubMed
1435850444Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.Ann Oncol2022https://conductscience.org/library/papers/35850444PubMed
1538602715Metal-Drug Coordination Nanoparticles and Hydrogels for Enhanced Delivery.Adv Mater2024https://conductscience.org/library/papers/38602715PubMed
1635968927Arginine Supplementation Targeting Tumor-Killing Immune Cells Reconstructs the Tumor Microenvironment and Enhances the Antitumor Immune Response.ACS Nano2022https://conductscience.org/library/papers/35968927PubMed
1735367839LncRNA-targeting bio-scaffold mediates triple immune effects for postoperative colorectal cancer immunotherapy.Biomaterials2022https://conductscience.org/library/papers/35367839PubMed
1837205768PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance.Sci Immunol2023https://conductscience.org/library/papers/37205768PubMed
1929449659Using immunotherapy to boost the abscopal effect.Nat Rev Cancer2018https://conductscience.org/library/papers/29449659PubMed
2027355859Synthesis of Monocrystalline Nanoframes of Prussian Blue Analogues by Controlled Preferential Etching.Angew Chem Int Ed Engl2016https://conductscience.org/library/papers/27355859PubMed

See all 53 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42011199

GET https://conductscience.org/api/papers/v1/42011199/references?page=2